Results 101 to 110 of about 777,237 (284)
Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin
Molecular Oncology, EarlyView.The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla +10 more
wiley +1 more source
Perturbations in neuroinflammatory pathways are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors. [PDF]
, 2019 Paclitaxel is a common chemotherapy drug associated with the development of chronic paclitaxel-induced peripheral neuropathy (PIPN). PIPN is associated with neuroinflammatory mechanisms in pre-clinical studies.
Abrams, Gary +9 more
core
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Targeting the tumor microenvironment in colorectal peritoneal metastases
, 2020 Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim +4 more
core +1 more source
Editorial: Sex Matters in Preclinical Research [PDF]
Molecular Endocrinology, 2014 In recent months, there has been a flurry of discussion regarding the importance of considering the sex of animals, primary cells, and even cell lines when performing preclinical studies. These conversations were highlighted in a recent editorial in Nature by Janine A. Clayton, Director of the National Institutes of Health Office of Research on Women’s
openaire +2 more sources
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
A novel closed-chest porcine model of chronic ischemic heart failure suitable for experimental research in cardiovascular disease [PDF]
, 2013 Cardiac pathologies are among the leading causes of mortality and morbidity in industrialized countries, with myocardial infarction (MI) representing one of the major conditions leading to heart failure (HF).
Antonio Amodeo +15 more
core +3 more sources
Preclinical research: Make mouse studies work [PDF]
Nature, 2014 More investment to characterize animal models can boost the ability of preclinical work to predict drug effects in humans, says Steve Perrin.
openaire +2 more sources
Targeting p38α in cancer: challenges, opportunities, and emerging strategies
Molecular Oncology, EarlyView.p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley +1 more source